CBIO
Income statement / Annual
Last year (2024), Crescent Biopharma, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Crescent Biopharma, Inc.'s net income was -$71.47 M.
See Crescent Biopharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$10.00 K |
$75.00 K |
$1.16 M |
$10.16 M |
$0.00 |
$0.00 |
$0.00 |
$18.50 K |
$20.07 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$899.30 K
|
$275.12 K
|
$263.54 K
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$10.00 K
|
$75.00 K
|
$1.16 M
|
$10.16 M
|
-$899.30 K
|
-$275.12 K
|
-$263.54 K
|
$0.00
|
$20.07 M
|
| Gross Profit Ratio |
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
1
|
| Research and Development Expenses |
$56.14 M
|
$20.07 M
|
$28.39 M
|
$47.49 M
|
$44.93 M
|
$47.03 M
|
$40.09 M
|
$24.10 M
|
$23.28 M
|
$25.05 M
|
| General & Administrative Expenses |
$12.63 M
|
$19.21 M
|
$19.09 M
|
$17.12 M
|
$16.74 M
|
$14.36 M
|
$11.41 M
|
$9.83 M
|
$8.65 M
|
$7.81 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$12.63 M
|
$19.21 M
|
$19.09 M
|
$17.12 M
|
$16.74 M
|
$14.36 M
|
$11.41 M
|
$9.83 M
|
$8.65 M
|
$7.81 M
|
| Other Expenses |
$0.00
|
$637.00
|
$443.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$68.76 M
|
$39.29 M
|
$47.48 M
|
$64.61 M
|
$61.67 M
|
$61.39 M
|
$51.51 M
|
$33.93 M
|
$31.93 M
|
$32.86 M
|
| Cost And Expenses |
$68.76 M
|
$39.29 M
|
$47.48 M
|
$64.61 M
|
$61.67 M
|
$61.39 M
|
$51.51 M
|
$33.93 M
|
$31.93 M
|
$32.86 M
|
| Interest Income |
$935.28 K
|
$2.38 M
|
$714.52 K
|
$19.77 K
|
$482.49 K
|
$3.50 M
|
$3.23 M
|
$0.00
|
$103.65 K
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$68.76 M
|
$153.30 K
|
$207.15 K
|
$264.60 K
|
$270.75 K
|
$899.30 K
|
$275.12 K
|
$263.54 K
|
$190.54 K
|
$191.48 K
|
| EBITDA |
$0.00 |
-$39.12 M |
-$47.20 M |
-$63.18 M |
-$51.24 M |
-$56.99 M |
-$51.23 M |
-$33.67 M |
-$31.72 M |
-$12.59 M |
| EBITDA Ratio |
0
|
-3912.14
|
-629.28
|
-54.48
|
-5.04
|
0
|
0
|
0
|
-1714.75
|
-0.63
|
| Operating Income Ratio |
0
|
-3927.53
|
-632.04
|
-54.71
|
-5.07
|
0
|
0
|
0
|
-1725.05
|
-0.64
|
| Total Other Income/Expenses Net |
-$2.70 M
|
$2.38 M
|
$714.96 K
|
$19.77 K
|
$482.49 K
|
$3.50 M
|
$3.23 M
|
$651.21 K
|
$103.65 K
|
$15.33 K
|
| Income Before Tax |
-$71.47 M
|
-$36.90 M
|
-$46.69 M
|
-$63.43 M
|
-$51.03 M
|
-$57.89 M
|
-$48.27 M
|
-$33.28 M
|
-$31.81 M
|
-$12.77 M
|
| Income Before Tax Ratio |
0
|
-3689.88
|
-622.51
|
-54.69
|
-5.02
|
0
|
0
|
0
|
-1719.45
|
-0.64
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$3.78 M
|
$3.23 M
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$71.47 M
|
-$36.90 M
|
-$46.69 M
|
-$63.43 M
|
-$51.03 M
|
-$54.12 M
|
-$48.27 M
|
-$33.28 M
|
-$31.81 M
|
-$12.77 M
|
| Net Income Ratio |
0
|
-3689.94
|
-622.52
|
-54.69
|
-5.02
|
0
|
0
|
0
|
-1719.45
|
-0.64
|
| EPS |
-0.59 |
-0.58 |
-0.89 |
-1.23 |
-1.12 |
-1.25 |
-1.18 |
-1.13 |
-1.5 |
-0.67 |
| EPS Diluted |
-0.59 |
-0.58 |
-0.89 |
-1.23 |
-1.12 |
-1.25 |
-1.18 |
-1.13 |
-1.5 |
-0.67 |
| Weighted Average Shares Out |
$64.48 M
|
$63.34 M
|
$52.53 M
|
$51.45 M
|
$45.72 M
|
$43.25 M
|
$41.04 M
|
$29.40 M
|
$21.26 M
|
$19.01 M
|
| Weighted Average Shares Out Diluted |
$64.48 M
|
$63.34 M
|
$52.53 M
|
$51.45 M
|
$45.72 M
|
$43.25 M
|
$41.04 M
|
$29.40 M
|
$21.26 M
|
$19.01 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
